Moelis & Co. (MC) is a renowned global independent investment bank that specializes in financial advisory services. The firm was established in 2007 by Ken Moelis and a group of senior bankers which has now evolved to a powerhouse of over 900 employees across 19 geographic locations including North America, South America, Europe, the Middle East, Asia, and Australia.
The core of Moelis & Co.'s business falls into offering strategic advice on mergers and acquisitions (M&A), recapitalizations and restructurings, as well as capital markets transactions. Their clientele spans from multinational corporations, sovereign wealth funds, private equity sponsors, family businesses, to government entities. Over the years, the firm has advised on transactions dealing with over $3 trillion in total deal value.
Moelis & Co. prides itself on its client-first approach. Not being attached to any underwriting, trading, research, or sales activities allows the firm to focus solely on its clients' long-term strategic interests. The firm is independent by choice and thus avoids any conflicts of interest often encountered by more compromise-prone larger institutions.
The firm champions a "one firm" culture that pulls together its global team to deliver the highest level of strategic advice. The firm's focus is on providing innovative solutions to complex business challenges in a globally integrated and seamless manner. This approach helps build long-term trusted relationships with clients, anticipating their needs, and providing tailored advisory services.
Their full-scale global operation enables them to grasp the unique context of each region thus providing a necessary local approach whilst ensuring global standards. This balanced global-local approach makes the firm stand out in the crowded investment banking market.
Innovation and responsiveness are key hallmarks of the firm. Moelis & Co. understands market dynamism and its implications on clients' operations and seeks to provide forward-looking solutions to help clients navigate the ever-changing business landscape.
Over the years, Moelis & Co. has been recognized for its excellence in advising and has bagged numerous awards. They are among the top 10 M&A advisors globally, underlining their reputation for consistently delivering high-caliber outcomes.
It is clear that Moelis & Co. has carved a niche in the investment banking sector. Thanks to its dedication to client service, focussed strategy advice and, commitment to innovation, the Moelis & Co. name has become synonymous with quality, integrity and exceptional results.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Nick Riehl, Principal Accounting Officer of Moelis & Co (NYSE:MC), recently acquired five tranches of dividend equivalent Restricted Stock Units (RSUs) on September 17, 2026. These acquisitions were made at a $0 conversion price and are linked to unvested underlying RSUs from various past grant programs, with their vesting aligned to the original grants. Following these transactions, Riehl's holdings in different RSU programs have increased, as detailed in the SEC Form 4 filing on September 21, 2026.
Kenneth Shropshire, a Director at Moelis & Co (NYSE:MC), acquired dividend equivalent Restricted Stock Units (RSUs) on September 17, 2026, as disclosed in a Form 4 filed with the SEC. These acquisitions include 20 units of 2025 Annual RSUs, 18.56 units of 2026 Annual RSUs, and 2.18 units of 2026 Elective RSUs, which will vest simultaneously with their underlying RSUs. Following these transactions, Shropshire directly holds a total of 1,851.67 units of 2025 Annual RSUs, 1,718.56 units of 2026 Annual RSUs, and 202.18 units of 2026 Elective RSUs.
Moelis & Co Director Laila Worrell acquired dividend equivalent Restricted Stock Units (RSUs) on September 17, 2026, as disclosed in a Form 4 filing with the SEC on September 21, 2026. These RSUs were granted across three categories (2025 Annual, 2026 Annual, and 2026 Elective) at no cost, representing Class A Common Stock, and will vest concurrently with their underlying RSUs.
_07_03_2026_03_50_21_133108.jpg)
Kenneth Shropshire, a Director at Moelis & Co (NYSE:MC), sold 1,881 shares of the company's Class A Common Stock on August 27, 2026, at a price of $69.06 per share. This transaction, revealed in a Form 4 SEC filing on August 31, 2026, leaves Shropshire with 7,633 shares of Class A Common Stock. The sale was an open-market transaction, and no Rule 10b5-1 trading plan was indicated.
Moelis & Company (NYSE:MC) Director Kenneth Shropshire recently sold 1,881 shares of the company's stock for approximately $129,901.86, reducing his holdings by nearly 20%. This sale follows the company's report of quarterly EPS that exceeded estimates and a 12% increase in revenue. Analysts currently maintain a consensus "Hold" rating for Moelis & Company, with an average target price of $73.62.
The potential US$400 billion merger talks between AstraZeneca and Bristol Myers Squibb have brought attention to the healthcare deal advisory sector. This article examines how this development could affect M&A activity and highlights three stocks—Huron Consulting Group (HURN), Gateley (Holdings) (GTLY), and Moelis (MC)—that appear well-positioned to benefit from increased deal-making in the pharmaceutical industry. It provides an overview of each company, their operations, market capitalization, and specific reasons why they are relevant to this theme, alongside their respective opportunities and risks.